10-Q: DarioHealth Reports Q2 2026 Results: Revenue Declines, Net Loss Narrows

DarioHealth Corp. announced its second-quarter 2026 financial results, showing a decrease in total revenues and a continued net loss, though operating expenses were reduced.

Summary

• DarioHealth Corp. reported total revenues of $5.177 million for the three months ended June 30, 2026, a decrease from $5.369 million in the same period of 2025.
• For the six months ended June 30, 2026, revenues were $10.760 million, down from $12.121 million in the prior year period.
• The company reported a net loss of $7.924 million for the three months ended June 30, 2026, compared to a net loss of $12.990 million in the prior year period.
• For the six months ended June 30, 2026, the net loss was $16.173 million, a decrease from $22.217 million in the same period of 2025.
• Operating expenses decreased across research and development, sales and marketing, and general and administrative categories.
• As of June 30, 2026, the company had $6.634 million in cash and cash equivalents, a significant decrease from $21.803 million at the end of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to continued net losses, declining revenues, and a significant cash burn, despite some operational cost reductions.

Positives

• Net loss narrowed significantly in both the three-month and six-month periods compared to the prior year.
• Operating expenses were reduced across R&D, sales & marketing, and G&A, indicating cost control measures.
• Gross profit margin improved to 61.7% for the three months and 59.4% for the six months ended June 30, 2026, up from 55.2% and 56.5% respectively in the prior year.
• A Fortune 50 employer selected DarioHealth for its integrated cardiometabolic care platform for over 100,000 employees.
• Expansion of relationship with a top-five U.S. health insurer to include hypertension care.
• Launch of an integrated GLP-1 program through licensed healthcare providers.
• Broader deployment of DarioIQ, its AI-powered engagement platform, across enterprise customers.

Negatives

• Total revenues decreased by 3.6% for the three months and 11.2% for the six months ended June 30, 2026, compared to the prior year.
• The company continues to incur significant net losses, with an accumulated deficit of $468.251 million as of June 30, 2026.
• Cash and cash equivalents significantly decreased to $6.634 million as of June 30, 2026, from $21.803 million at December 31, 2025.
• Net cash used in operating activities was $12.108 million for the six months ended June 30, 2026.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funds.
• The decrease in revenues was primarily due to a decline in pharma channel revenue, attributed to non-recurring revenue from a prior-year pharmaceutical partner.

Risks

• The company has incurred recurring losses and negative cash flows since inception and has an accumulated deficit of $468,251.
• Management believes the company has sufficient funds for at least twelve months from the issuance date, but expects future net losses and dependence on raising additional funds.
• There are no assurances that the company will be able to obtain adequate financial resources for long-term development and commercialization.
• Global trade policy continues to evolve, and the ultimate impact of recent developments with respect to U.S. tariffs remains uncertain.
• The company's business, financial condition, and results of operations could be materially affected by various risks, uncertainties, and other factors, including those detailed in its Form 10-K.

Future Outlook

Management believes the company has sufficient funds to support operations for at least twelve months from the issuance date of the financial statements, supported by recent capital raises. However, the company expects to incur future net losses and its transition to profitability is dependent on successful commercialization and achieving adequate revenue levels. It will continue to depend on raising additional funds.

Management Comments

• We believe that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack of relevance, personalization, consumerization, and longitudinal data and information.
• We first deliver engagement followed by sustained behavior change that then leads to measurable health outcomes and improvement.
• Management believes that the proceeds from the Purchase Agreement, combined with our cash on hand and short-term bank deposits are sufficient to meet our obligations as they come due for at least a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.
• There are no assurances, however, that we will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of our product offerings.

Industry Context

StockSavvy.ai notes that DarioHealth operates in the highly competitive digital therapeutics (DTx) market, which is seeing increased investment and consolidation. The company's focus on a 'whole-person' health approach, integrating physical and mental health with AI and coaching, aligns with broader industry trends towards personalized and data-driven care. However, the continued revenue decline and cash burn highlight the challenges in scaling DTx solutions and achieving profitability in this sector.

Comparison to Industry Standards

• The company's revenue decline in the pharma channel due to non-recurring revenue is a common challenge for companies relying on large, one-off contracts.
• The improved gross profit margin is a positive sign, suggesting better cost management on delivered services and products, which is a key metric for profitability in the DTx sector.
• The significant reduction in operating expenses, particularly R&D and G&A, indicates a focus on efficiency, which is crucial for early-stage or growth-stage companies in the health tech industry that often face pressure to demonstrate a path to profitability.
• The company's cash position and reliance on future funding are typical for many companies in the digital health space, which often require substantial investment before reaching sustainable revenue and profitability.

Legal Proceedings

• The company is involved in claims and legal proceedings from time to time, but no specific details are provided in this filing.

Related Party Transactions

• A non-executive director is a member of a consulting firm that provides investment and business consulting services to the Company. The firm receives a monthly cash retainer and has been issued restricted shares and warrants.

Stakeholder Impact

• Shareholders: Continued net losses and reliance on future capital raises may impact share value and dilution.
• Creditors: The company has a significant long-term loan, and its ability to meet obligations depends on its financial performance and access to capital.
• Employees: Cost-saving measures, including R&D and G&A reductions, could potentially impact staffing levels or resources.
• Customers: The company's ability to deliver on new contracts and expand services depends on its financial stability and operational execution.

Next Steps

• Commercial launch of the integrated cardiometabolic care platform for a Fortune 50 employer expected in the second half of 2026.
• Continued expansion of commercial footprint through new customer awards and expanded relationships.
• Further enhancements to its AI-powered chronic condition management platform.
• Management will continue to seek additional funding to support future operations and development.

Key Dates

Recommendation

While DarioHealth has shown progress in reducing operating expenses and improving gross margins, the continued decline in revenue and significant cash burn necessitate a cautious approach. The recent capital raise provides some runway, but the path to profitability remains uncertain. A 'hold' recommendation reflects the balance between potential upside from new contracts and the inherent risks associated with the company's financial situation and market execution.

Keywords

digital therapeutics, chronic condition management, health intelligence, behavior change, AI, telehealth, healthcare platform, cardiovascular health